Growing evidence from Th cell-mediated disorders, such as inflammatory bowel diseases suggests IL-36γ binds to receptors on CD4+ T cells, potently inhibiting Foxp3-expressing induced regulatory T cell (Treg) development, while IL36 could promote Th9 cells differentiation via a IL-2-STAT5 and IL-4-STAT6-dependent pathway 27. The gene discussed is IL36G; the disease is inflammatory bowel disease.